Helsinn Group SA, a Swiss pharmaceutical group that specialises in products for cancer and rare diseases, has announced the appointment of Mary Lynne Hedley to its board of directors. Dr Hedley is an immunologist and cancer cell biologist who until recently was president and chief operating officer of Tesaro Inc, which she co-founded in 2010. The company was bought by GlaxoSmithKline Plc in 2019.
Dr Hedley received her doctorate in molecular and cellular immunology from UT Southwestern Medical Center and carried out postdoctoral training at Harvard University, both in the US.
Helsinn announced the appointment on 29 April 2021.
Copyright 2021 Evernow Publishing Ltd